and drug administration requested more information regarding the the company's generic version of teva pharmaceuticals' multiple sclerosis treatment. the news rattles investors concerned about a possible delay. mile mylan's shares were down, as were teva's. >>> and a regulatory filing revealed that the department of justice recently launched a civil and criminal investigation into booz allen hamilton's cost accounting and indirect cost charging practices. the accounting firm says it hasn't uncovered deficiencies through its auditing but is coordinating with the investigation. shares initially plunged in afterhours trading and ended the regular session down marginally to $39.33. >>> the most popular 401(k) funds are crowded with some of the most popular and right now most volatile names in tech. the top three funds are loaded with tech names like facebook, amazon, apple, alphabet, the parent company of google. vanguard, the fidelity growth company. what does it mean for you? ken mahoney joins us now to discuss this, ken, good to see you. let's put this in perspective. over the year, tec

. >>> teva stock has dropped sharply because of delays in acquisitions >>> western digital reportedlyonsidering raising its offer for toshiba's chip unit to more than $18 billion. western digital's ceo told toshiba's president the company plans to join a consortium that includes kkr and a development bank of japan to compete with a rival off >>> amazon started hiring people to sell cars online in europe. a german straytrade magazine sah company will run the business out of luxembourg. >>> and shares of diebold could rise 25% to 40% over the next two years. the atmmaker should be able to raise margins and earnings thanks to cost synergies and the merger last year. >>> prime minister theresa may faces a showdown today as her political future hangs in the balance. all the fallout from that extraordinary vote last week and much more coming up on "worldwide exchange. these days families want to be connected 24/7. that's why at comcast, we're always working to make our services more reliable. with technology that can update itself. and advanced fiber network infrastructure. new, more reliab

. >>> glaxosmithkline winning a 2$235 million award from teva i a patent trial >> patent. >> well, ist patent? >> i have to correct you on that one. >> i will stick with patent. maybe you're right >> maybe >> new field exploration shares. the falling oil prices weighing on the sector. that stock is off 3% >>> and imagination technologies putting itself up for sale this coming weeks after the chip designeder launched a formal dispute against apple. down -- we don't have the share price. maybe we won't >>> bill girlurley has stepped n from his role at uber. he will be replaced by a colleague from his investment firm benchmark.wisher of re/codd him. board member, but also praising kalanick afterwards saying he will be remembered as one of the greats his name got caught up in it maybe decided tostep aside to leave room for a new era >> still a board seat kept by his company. just a slight change versus the massive changes at the executive level. so many positions to fill. they have a management executive committee of ten people overseeing everything. i wonder if this is the time for lyft

>> caller: doing all right so i was looking at teva pharmaceutical looks like a great company biggest manufacturer of manufactured drugs in the world. great drugs coming down the pipeline his tough times. acquisition, ceo and cfo leaving and replacing four members of board of directors fli s in add to a new ceo what do you think? share is low >> when they, remember, bought allergan, when they bought allergan's generic, they gave -- they gave allergan a huge slug of stock, which in a couple months will be for sale in order to be able to clean up teva's -- the balance sheets better. i say, no. don't buy. >> don't buy, don't buy. >> don't think it's the right place to be. all right, a lot of cross-currents right now, although iheaded higher. we need to hear janet yellen say 9 right thing. sports flying in emerson electric but it the stock continue to amp up the juice plugging in the profits. capping technicals and shining a like on the company and big downgrade of energy related stock made waves last week the worst part, i think the waves are dead right ma make sure this company isn't lu

it includes johnson & johnson, teva pharmaceuticals and allergan. purdue says it shares the attorney general's concerns. johnson & johnson called the allegations unfunded. >>> the maker of epipens may have overcharged the government more than a billion dollars for epipens. the department of health and human services said between 2006 and 2016, the u.s. government may have overpaid mylan. that dollar amount is nearly three times a proposed settlement that the company announced in october. mylan says the company continues to work with the government to finalize that settlement. >>> north carolina's largest health insurer may increase rates by more than 20% for the second year in a row, tied to uncertainty over subsidies for low income enrollees. >> this is an urgent situation. we simply need to know what the rules of the game are going to be for 2018 in order to hit affordability as well as stability. >> if those cost sharing subsidies are funded next year, blue cross of north carolina says it will still need to raise rates but by only about 8.5%, not

all allergen has no comment, johnson&johnson says the accusations are unfounded and teva says it is importantrtant public health issues relating to opioids, rather than litigation. and purdue pharma told us "we share the attorney general's concerns about the opioid crisis. we are committed to working collaboratively to find solutions." joining us now is the attorney general of ohio, mike dewine. thank you for being here. >> good morning. thank you. >> good morning. so, let's get to the evidence, because everyone agrees that the opioid crisis is real, it is urgent, it is devastating american families and claiming far too many lives. the question is who's to blame. so, your lawsuit takes on big pharma, takes on the big drug makers, and it states that these companies overstated the benefits of prescription opioids and understated the risks. you say the evidence shows that they did this to boost profits and deceive physicians who were prescribing these. what's the core of the evidence there? >> well, this we will show in court when we go to court. there's been a consistent pattern year after year

attorney general mike dewine filed a lawsuit against purdue pharma, the maker of oxycontin, as well as tevaaceuticals and johnson & johnson, accusing the companies of spending millions on marketing campaigns that "trivialize the risks of opioids while overstatating the benefits of using them for chronic pain." similar lawsuits have been filed in washington, new york, illinois, mississippi, california. for more on the epidemic, we're joined by dr. andrew kolodny, co-director of opioid policy research at the heller school for social policy and management at brandeis university. he is also co-founder and director of f physicians for responsible opioid prescribing. welcome to democracy now! can you respond to both the epidemic and opioid use and deaths and also how the trump administration is proposing to deal with it? suck sure. happy too. >> sure. happy too. u.s. is in the midst of its worst epidemic in history. i'm referring to the number of people addicted and the number of people dying from overdose deaths. the epidemic began 20 years ago and has gotten worse every year steadily. as you me

today's leaders include microron, hp ink, teva pharmaceuticals, johnson trolls and target >>> we are back on halftime. we sent pete najarian to the te telestraiter he's looking for unusual options activity and you found it in >> i'm looking at lowe's scott we talk about home depot all the time, a little bit less about lowe's it's interesting to see. if you take a look at this chart, it looks absolutely fantastic. if you get here towards may, you start to see a little bit of a breakdown. where i'm putting this line right here, that's give or take close to about the 50-day moving average. in other words, it broke through that moving average, it continued down, it did test it again, and then pulled right back down once again you can see that maybe the stock is struggling a little bit right now. i talk about calls all the time. today i'm going to talk about puts i don't think they're protecting i think somebody's out there and thinks this stock actually has some downside. they came out and fairly aggressively, these july 75.5 puts you can see, over 5,000 of these were bought today. they

teva. >>> crude oil has dropped 20% since peaking in late february with only brief rallies, crude hashe end of 2016 in the wake of that initial opec led production cut. jackie joins us more with where prices could be heading pinpoint something crazy. below 35 >> it's possible at this point look we tested $42 a barrel yesterday. it's clear the market is pricing in an extended period of oversupply here. could mean more pain is ahead. there could be more risks hide when oil is near $26 in february of last year the concern was the impact on the credit market. i'm starting to hear that conversation again and it's important. analysts and traders are checking high yields energy spread to determine if more danger is looming. take a look at this chart from s&p dow jones indices. look at the dip in february in if index in 2016 it doesn't look like we're in the danger zone just yet but oil is holding over $40 a barrel while many producers used technology to bring down the break even cost a three handle will squeeze if we see a two handle down the line maybe in the fall, risks of defaults increas

actions by management and its board in a new letter to shareholders the generic drugmaker says an off by tevas not good for the company another offer was a strategic move all of this comes ahead of the june 22nd annual meeting >>> nba hall of famer dennis rodman arriving in north korea earlier this morning this is his first visit to the country since president trump took office. rodman has received the red carpet treatment every time he's gone there on each of his past visits he's been criticized for making the trips during times of high tension between the u.s. and north korea. all right let's get back to our guest host for the hour, ron baron, ceo and chief investment officer at baron capital we're all obsessed with tesla. when will you hear when you were talking about 350 to 400, ron? >> six months ago, maybe >> six months ago. >> so at the beginning of the year, one of the executives at tesla asked me what i thought -- >> below 200 >> and he asked me what i thought the stock would do this year and i said i thought with the introduction of model 3, i thought the stock sometime this year wo